Table 3

Multivariate analyses comparing 21FK score with other survival prognostic factors in the CLL cohort and CLL validation cohort

PHR95% CI
LowerUpper
CLL cohort (n = 104)     
    B2M (≤ 4 mg/L vs > 4 mg/L) .029 3.861 1.152 12.987 
    CD19+CD38+ (≤ 34% vs > 34%) .209 2.365 0.618 9.050 
    IgVH (nonmutated vs mutated) .026 10.638 1.330 83.333 
    ZAP-70 (> 20% vs < 20%) .120 2.642 0.778 8.976 
    21FK score (2/2 vs 1/2 vs 0/2) .007 3.514 1.409 8.76 
CLL validation cohort (n = 80)     
    IgVH (nonmutated vs mutated) .640 7.082 0.002 NA 
    ZAP-70 (≤ 20% vs > 20%) .690 5.311 0.001 NA 
    21FK score (high vs low) .013 5.217 1.408 19.327 
PHR95% CI
LowerUpper
CLL cohort (n = 104)     
    B2M (≤ 4 mg/L vs > 4 mg/L) .029 3.861 1.152 12.987 
    CD19+CD38+ (≤ 34% vs > 34%) .209 2.365 0.618 9.050 
    IgVH (nonmutated vs mutated) .026 10.638 1.330 83.333 
    ZAP-70 (> 20% vs < 20%) .120 2.642 0.778 8.976 
    21FK score (2/2 vs 1/2 vs 0/2) .007 3.514 1.409 8.76 
CLL validation cohort (n = 80)     
    IgVH (nonmutated vs mutated) .640 7.082 0.002 NA 
    ZAP-70 (≤ 20% vs > 20%) .690 5.311 0.001 NA 
    21FK score (high vs low) .013 5.217 1.408 19.327 

CLL indicates chronic lymphocytic leukemia; HR, hazard ratio; CI, confidence interval; B2M, β-2 microglobulin; IgVH, immunoglobulin heavy-chain variable-region gene; ZAP-70, 70-kDa ζ-associated protein; 21FK, miR-21, FISH, and Karyotype score; and NA, not available.

or Create an Account

Close Modal
Close Modal